Publications by authors named "Paula Krone"
Background: The CDK4/6 inhibitor abemaciclib is an FDA-approved agent and induces T-cell-mediated immunity. Previously, we confirmed the therapeutic potential of abemaciclib on mismatch repair-deficient (dMMR) tumors in mice. Here, we applied a prophylactic administration/dosage setting using two preclinical mouse models of dMMR-driven cancer.
View Article and Find Full Text PDFWide-spread cancer-related immunosuppression often curtails immune-mediated antitumoral responses. Immune-checkpoint inhibitors (ICIs) have become a state-of-the-art treatment modality for mismatch repair-deficient (dMMR) tumors. Still, the impact of ICI-treatment on bone marrow perturbations is largely unknown.
View Article and Find Full Text PDFArticle Synopsis
- dMMR tumors respond well to immune checkpoint inhibitors, but resistance can hinder treatment success.
- The study compared the effects of an α-PD-L1 antibody and the CDK4/6 inhibitor abemaciclib in mouse models, finding that abemaciclib significantly improved survival compared to α-PD-L1.
- The treatment with abemaciclib led to increased immune cell activity, reduced T cell exhaustion, and higher expression of DNA repair genes, suggesting it may be a suitable option for dMMR patients who can’t use ICIs.